CR10923A - Nuevos compuestos y sus efectos sobre el conductismo de la alimentacion - Google Patents

Nuevos compuestos y sus efectos sobre el conductismo de la alimentacion

Info

Publication number
CR10923A
CR10923A CR10923A CR10923A CR10923A CR 10923 A CR10923 A CR 10923A CR 10923 A CR10923 A CR 10923A CR 10923 A CR10923 A CR 10923A CR 10923 A CR10923 A CR 10923A
Authority
CR
Costa Rica
Prior art keywords
conducting
food
effects
new compounds
compounds
Prior art date
Application number
CR10923A
Other languages
English (en)
Inventor
Bloom Stephen
Original Assignee
Imp Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0624868.6A external-priority patent/GB0624868D0/en
Priority claimed from GB0625667A external-priority patent/GB0625667D0/en
Priority claimed from GB0700897A external-priority patent/GB0700897D0/en
Application filed by Imp Innovations Ltd filed Critical Imp Innovations Ltd
Publication of CR10923A publication Critical patent/CR10923A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Birds (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CR10923A 2006-12-13 2009-07-13 Nuevos compuestos y sus efectos sobre el conductismo de la alimentacion CR10923A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0624868.6A GB0624868D0 (en) 2006-12-13 2006-12-13 Novel compounds and their effects on feeding behaviour
GB0625667A GB0625667D0 (en) 2006-12-21 2006-12-21 Novel compounds and their effects on feeding behaviour
GB0700897A GB0700897D0 (en) 2007-01-17 2007-01-17 Novel compounds and their effects on feeding behaviour

Publications (1)

Publication Number Publication Date
CR10923A true CR10923A (es) 2009-11-09

Family

ID=39106277

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10923A CR10923A (es) 2006-12-13 2009-07-13 Nuevos compuestos y sus efectos sobre el conductismo de la alimentacion

Country Status (22)

Country Link
US (3) US8101576B2 (es)
EP (2) EP1985304A3 (es)
JP (1) JP5669395B2 (es)
KR (1) KR20090098843A (es)
AR (1) AR064334A1 (es)
AU (1) AU2007331257B2 (es)
BR (1) BRPI0721093A2 (es)
CA (1) CA2672406A1 (es)
CO (1) CO6210830A2 (es)
CR (1) CR10923A (es)
EC (1) ECSP099513A (es)
GT (1) GT200900163A (es)
IL (1) IL199247A (es)
MX (1) MX2009006348A (es)
MY (1) MY152840A (es)
NI (1) NI200900116A (es)
NZ (1) NZ578213A (es)
RU (1) RU2492183C2 (es)
SG (1) SG177226A1 (es)
SV (1) SV2009003297A (es)
TW (1) TWI428346B (es)
WO (1) WO2008071972A1 (es)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
AU2002332054B2 (en) * 2001-09-24 2007-11-08 Imperial Innovations Limited Modification of feeding behavior
US8058233B2 (en) * 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
AU2007284759B2 (en) 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
RU2440097C2 (ru) 2007-04-23 2012-01-20 Интарсия Терапьютикс, Инк. Способ лечения диабета ii типа и ожирения, осмотическое устройство для доставки и способ его изготовления
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
KR101593406B1 (ko) 2008-12-15 2016-02-12 질랜드 파마 에이/에스 글루카곤 유사체
JP5635529B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
CA2747112A1 (en) 2008-12-15 2010-06-24 Zealand Pharma A/S Glucagon analogues
KR20110126591A (ko) 2008-12-15 2011-11-23 질랜드 파마 에이/에스 글루카곤 유사체
ES2537287T3 (es) 2009-07-13 2015-06-05 Zealand Pharma A/S Análogos de glucagón acilados
US20120148586A1 (en) 2009-08-27 2012-06-14 Joyce Ching Tsu Chou Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
EP3735944A1 (en) 2009-09-28 2020-11-11 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
AR079344A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
AR079345A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina
US20130157953A1 (en) 2010-01-20 2013-06-20 Zealand Pharma A/S Treatment of cardiac conditions
JP6054861B2 (ja) * 2010-03-26 2016-12-27 ノヴォ ノルディスク アー／エス 新規のグルカゴン類似体
SG184988A1 (en) 2010-04-27 2012-11-29 Zealand Pharma As Peptide conjugates of glp-1 receptor agonists and gastrin and their use
JP6050746B2 (ja) * 2010-05-13 2016-12-21 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation Ｇタンパク質共役受容体活性を示すグルカゴンスーパーファミリーのペプチド
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
MX2012014961A (es) 2010-06-24 2013-02-26 Zealand Pharma As Analogos de glucagon.
US20140011733A1 (en) 2011-01-20 2014-01-09 Zealand Pharma A/S Combination of acylated glucagon analogues with insulin analogues
GB201101459D0 (en) 2011-01-27 2011-03-16 Imp Innovations Ltd Novel compounds and thier effects on fedding behaviour
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
WO2012153196A2 (en) 2011-05-10 2012-11-15 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
EP3434687B1 (en) 2011-06-10 2021-03-10 Hanmi Science Co., Ltd. Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
CN109306015B (zh) 2011-06-17 2022-04-26 韩美科学株式会社 包括泌酸调节肽和免疫球蛋白片段的结合物以及其应用
EP2729493B1 (en) * 2011-07-04 2020-06-10 IP2IPO Innovations Limited Novel compounds and their effects on feeding behaviour
TWI596110B (zh) 2011-09-23 2017-08-21 諾佛 儂迪克股份有限公司 新穎升糖素類似物
KR20140100947A (ko) 2011-11-03 2014-08-18 질랜드 파마 에이/에스 Ｇｌｐ-1 수용체 효능제 펩타이드 가스트린 접합체들
NZ702333A (en) 2012-05-03 2017-06-30 Zealand Pharma As Gip-glp-1 dual agonist compounds and methods
AR091422A1 (es) 2012-06-14 2015-02-04 Sanofi Sa Analogos peptidicos de la exendina 4
CA2878991C (en) 2012-07-23 2021-12-07 Zealand Pharma A/S Glucagon analogues
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
CA2890324C (en) 2012-11-06 2021-02-23 Hanmi Pharm. Co., Ltd. Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
HUE035803T2 (en) 2012-12-21 2018-05-28 Sanofi Sa Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
US10087221B2 (en) 2013-03-21 2018-10-02 Sanofi-Aventis Deutschland Gmbh Synthesis of hydantoin containing peptide products
ES2624961T3 (es) 2013-03-21 2017-07-18 Sanofi-Aventis Deutschland Gmbh Síntesis de productos de péptido que contienen imida cíclica
AR095986A1 (es) 2013-04-03 2015-11-25 Sanofi Sa Proteínas modificadas que regulan glucosa en sangre con perfil alterado de actividad farmacológica y preparación de las mismas
AU2014255608B2 (en) 2013-04-18 2018-01-25 Novo Nordisk A/S Stable, protracted GLP-1/glucagon receptor co-agonists for medical use
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
US9896495B2 (en) 2013-10-17 2018-02-20 Zealand Pharma A/S Acylated glucagon analogues
JP6682432B2 (ja) 2013-11-06 2020-04-15 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
KR102310392B1 (ko) 2013-11-06 2021-10-13 질랜드 파마 에이/에스 글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
WO2015086731A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
CN106536547A (zh) 2014-06-04 2017-03-22 诺和诺德股份有限公司 用于医疗用途的glp‑1/胰高血糖素受体共激动剂
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
TWI772252B (zh) 2014-09-16 2022-08-01 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
CN106519015B (zh) * 2014-09-23 2020-04-17 深圳市图微安创科技开发有限公司 胃泌酸调节素类似物
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
WO2016066744A2 (en) 2014-10-29 2016-05-06 Zealand Pharma A/S Gip agonist compounds and methods
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
KR20170137198A (ko) 2015-04-16 2017-12-12 질랜드 파마 에이/에스 아실화된 글루카곤 유사체
MA44390A (fr) 2015-06-03 2019-01-23 Intarcia Therapeutics Inc Systèmes de mise en place et de retrait d'implant
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
WO2016198628A1 (en) 2015-06-12 2016-12-15 Sanofi Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
WO2017200943A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
AR110299A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico
MX2019006486A (es) 2016-12-09 2019-08-01 Zealand Pharma As Agonistas duales acilados de glp-1/glp-2.
IL267736B2 (en) 2017-01-03 2024-03-01 Intarcia Therapeutics Inc Methods involving continuous administration of a GLP-1 receptor agonist and co-administration of a drug
RU2670983C1 (ru) * 2017-10-11 2018-10-29 Федеральное государственное бюджетное учреждение "Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов Национального исследовательского центра "Курчатовский институт" (НИЦ "Курчатовский институт" - ГосНИИгенетика) Применение полипептида, полученного на основе глюкагоноподобного пептида 1 человека, в качестве средства для контроля за весом тела
JP2018090636A (ja) * 2018-03-15 2018-06-14 インペリアル・イノベイションズ・リミテッド 新規化合物及び摂食行動に対するそれらの効果
EP3901173A4 (en) 2018-12-21 2022-11-23 Jiangsu Hengrui Medicine Co., Ltd. BISPECIFIC PROTEIN
WO2024108209A1 (en) * 2022-11-18 2024-05-23 The Trustees Of The University Of Pennsylvania Compositions and methods for controlling food intake, energy expenditure, and body weight for the treatment of obesity and metabolic diseases

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4223017A (en) 1975-04-15 1980-09-16 Burroughs Wellcome Co. Biologically active amides
US4175122A (en) 1975-04-15 1979-11-20 Burroughs Wellcome Co. Biologically active amides
GB1560933A (en) 1975-04-15 1980-02-13 Wellcome Found Biologically activy polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4220653A (en) 1979-01-24 1980-09-02 Vivino A Earl Administration of cimetidine to reduce appetite and facilitate weight loss in persons suffering from excessive weight
US4229389A (en) 1979-03-16 1980-10-21 Thompson Marine Corporation Gas diffuser, aerator, or sparger apparatus
EP0052322B1 (de) 1980-11-10 1985-03-27 Gersonde, Klaus, Prof. Dr. Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur Durchführung des Verfahrens
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
ATE59966T1 (de) 1983-09-26 1991-02-15 Ehrenfeld Udo Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr.
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4701441A (en) 1985-02-11 1987-10-20 University Of Florida Methods and compositions for stimulation of appetite
US4698327A (en) 1985-04-25 1987-10-06 Eli Lilly And Company Novel glycopeptide derivatives
CA1257199A (en) 1986-05-20 1989-07-11 Paul Y. Wang Preparation containing bioactive macromolecular substance for multi-months release in vivo
HU196755B (en) 1986-09-16 1989-01-30 Gyogyszerkutato Intezet Process for production of new substituated amilid derivatives and medical compositions containing them
IE63869B1 (en) 1986-11-06 1995-06-14 Res Dev Foundation Aerosols containing liposomes and method for their preparation
US5026685A (en) 1988-07-15 1991-06-25 The Salk Institute For Biological Studies NPY peptide analogs
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
ATE135370T1 (de) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
SE9002278L (sv) 1990-06-28 1991-12-29 Perstorp Ab Anvaendning av inositoltrisfosfat foer framstaellning av ett laekemedel
IT1243390B (it) 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US5175122A (en) * 1991-06-28 1992-12-29 Digital Equipment Corporation Planarization process for trench isolation in integrated circuit manufacture
US5571695A (en) 1991-11-06 1996-11-05 Garvan Institute Of Medical Research Human neuropeptide Y-Y1 receptor
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
DE69317110T2 (de) 1992-10-28 1998-10-08 Kuraray Co., Ltd., Kurashiki, Okayama Polyurethan sowie daraus hergestellte lederähnliche folie
JP2961045B2 (ja) 1993-02-24 1999-10-12 日清製粉株式会社 腸管粘膜増強促進剤
NZ265452A (en) 1993-03-29 1997-09-22 Univ Cincinnati Analogues of peptide yy, dimers and pharmaceutical compositions
WO1995000162A1 (en) 1993-06-21 1995-01-05 Enzon, Inc. Site specific synthesis of conjugated peptides
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5965566A (en) 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5880131A (en) 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5545549A (en) 1994-02-03 1996-08-13 Synaptic Pharmaceutical Corporation DNA encoding a human neuropeptide Y/peptide YY (Y2) receptor and uses thereof
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5696093A (en) 1994-10-28 1997-12-09 Crc For Biopharmaceutical Research Pty Limited Method of treating nasal congestion using neuropeptide Y Y2 agonist peptides
EP0791009A4 (en) 1994-11-07 2003-03-05 Merck & Co Inc MODIFIED NEUROPEPTIDE Y RECEPTOR
EP0795562A4 (en) 1994-11-07 2000-08-09 Kyowa Hakko Kogyo Kk NEW OXYNTOMODULINE
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
US5602024A (en) 1994-12-02 1997-02-11 Synaptic Pharmaceutical Corporation DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof
US5989920A (en) 1994-12-02 1999-11-23 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5
US5907030A (en) 1995-01-25 1999-05-25 University Of Southern California Method and compositions for lipidization of hydrophilic molecules
US5912227A (en) 1995-01-27 1999-06-15 North Carolina State University Method of enhancing nutrient uptake
US6558708B1 (en) 1995-05-17 2003-05-06 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
US5635503A (en) 1995-06-07 1997-06-03 Bristol-Myers Squibb Company Dihydropyridine npy antagonists: piperazine derivatives
WO1997019682A1 (en) 1995-12-01 1997-06-05 Synaptic Pharmaceutical Corporation Aryl sulfonamide and sulfamide derivatives and uses thereof
PT877599E (pt) 1996-02-02 2003-08-29 Alza Corp Administracao continua de leuprolido utilizando um sistema implantavel
US5962270A (en) 1996-02-06 1999-10-05 Bionebraska, Inc. Recombinant preparation of calcitonin fragments and use thereof in the preparation of calcitonin and related analogs
US5919901A (en) 1996-04-08 1999-07-06 Bayer Corporation Neuropeptide Y receptor Y5 and nucleic acid sequences
US5965392A (en) 1996-04-08 1999-10-12 Bayer Corporation Neuropeptide Y receptor Y5 and nucleic acid sequences
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
AUPO029096A0 (en) 1996-06-05 1996-07-04 Crc For Biopharmaceutical Research Pty Ltd Npy y2 agonists
US6355478B1 (en) 1996-06-17 2002-03-12 Eli Lilly And Company Rhesus monkey neuropeptide Y Y2 receptor
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
EP1826216A1 (en) 1996-08-30 2007-08-29 Novo Nordisk A/S Glp-1 derivatives
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
ATE289517T1 (de) 1996-11-12 2005-03-15 Novo Nordisk As Verwendung von glp-1 peptiden
AU1159897A (en) 1996-11-13 1998-06-03 University Of Cincinnati, The Analogs of peptide yy and uses thereof
DK1629849T4 (en) 1997-01-07 2017-12-04 Amylin Pharmaceuticals Llc Pharmaceutical compositions comprising exedins and agonists thereof
JP2001508783A (ja) 1997-01-29 2001-07-03 ポリマスク・ファーマシューティカルズ・パブリック・リミテッド・カンパニー Ｐｅｇ化法
US6048900A (en) 1998-02-13 2000-04-11 Bayer Corporation Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists
US6001836A (en) 1997-05-28 1999-12-14 Bristol-Myers Squibb Company Dihydropyridine NPY antagonists: cyanoguanidine derivatives
US5889016A (en) 1997-06-26 1999-03-30 Bristol-Myers Squibb Company Dihydropyrimidone derivatives as NPY antagonists
US6093692A (en) 1997-09-25 2000-07-25 The University Of Southern California Method and compositions for lipidization of hydrophilic molecules
EP0920864A1 (en) 1997-12-03 1999-06-09 Pfizer Products Inc. Combination therapy including a specific beta-3 agonist and an anorectic agent
JP2002501889A (ja) 1998-02-02 2002-01-22 トラスティーズ オブ タフツ カレッジ グルコース代謝を調節する方法、およびそれに関連する試薬
FR2774674B1 (fr) 1998-02-10 2000-03-24 Atochem Elf Sa Procede de preparation d'une solution aqueuse de peroxyde d'hydrogene directement a partir d'hydrogene et d'oxygene et dispositif permettant sa mise en oeuvre
JP2002506792A (ja) 1998-02-27 2002-03-05 ノボ ノルディスク アクティーゼルスカブ Ｎ末端修飾ｇｌｐ−１誘導体
US6046167A (en) 1998-03-25 2000-04-04 University Of Cincinnati Peptide YY analogs
FR2777283B1 (fr) 1998-04-10 2000-11-24 Adir Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5993414A (en) 1998-04-23 1999-11-30 Medtronic, Inc. Implantable device
ATE269846T1 (de) 1998-04-29 2004-07-15 Ortho Mcneil Pharm Inc N-substituierte aminotetraline als neuropeptid y y5 rezeptor-liganden und ihre anwendung zur behandlung von fettleibigkeit und anderen erkrankungen
DE69922676T2 (de) 1998-10-07 2005-12-15 Ortho-Mcneil Pharmaceutical, Inc. N-aralkylaminotetraline als neuropeptid-y-y5-rezeptorliganden
TWI242000B (en) 1998-12-10 2005-10-21 Univ Southern California Reversible aqueous pH sensitive lipidizing reagents, compositions and methods of use
WO2000042026A1 (en) 1999-01-15 2000-07-20 Novo Nordisk A/S Non-peptide glp-1 agonists
ES2353728T3 (es) 1999-02-10 2011-03-04 Curis, Inc. Péptido yy (pyy) para tratar trastornos metabólicos de la glucosa.
US6407120B1 (en) 1999-02-18 2002-06-18 Pfizer Inc. Neuropeptide Y antagonists
EP1165519A1 (en) 1999-04-02 2002-01-02 Neurogen Corporation Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics
US6340683B1 (en) 1999-04-22 2002-01-22 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (triazines)
US6218408B1 (en) 1999-06-30 2001-04-17 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (bicyclics)
EP1177172A1 (en) 1999-05-05 2002-02-06 Ortho-McNeil Pharmaceutical, Inc. 3a,4,5,9b-TETRAHYDRO-1H-BENZ e]INDOL-2-YL AMINE-DERIVED NEUROPEPTIDE Y RECEPTORS LIGANDS USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
AU5325200A (en) 1999-06-21 2001-01-09 Eli Lilly And Company Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat metabolic instability associated with non-insulin dependent diabetes
US6225330B1 (en) 1999-06-30 2001-05-01 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (tricyclics)
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US6399631B1 (en) 1999-07-23 2002-06-04 Pfizer Inc. Carbazole neuropeptide Y5 antagonists
CA2380032A1 (en) 1999-07-28 2001-02-08 Ortho-Mcneil Pharmaceutical, Inc. Amine and amide derivatives as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
WO2001014386A1 (fr) 1999-08-25 2001-03-01 Banyu Pharmaceutical Co., Ltd. Nouveaux dérivés isoindole
CA2381111A1 (en) 1999-08-26 2001-03-01 Leah M. Giupponi Npy antagonists: spiroisoquinolinone derivatives
AU6798000A (en) 1999-08-26 2001-03-19 Viropharma Incorporated Compounds, compositions and methods for treating influenza
IL148905A0 (en) 1999-09-30 2002-09-12 Neurogen Corp Pfizer Inc Certain alkylene diamine-substituted pyrazolo{1,5,-a}-1,5-pyrimidines and pyrazolo{1,5,-a}-1,3,5-triazines
AU1269501A (en) 1999-11-12 2001-05-30 Novo Nordisk A/S Use of glp-1 agonists for the inhibition of beta cell degeneration
US6436091B1 (en) 1999-11-16 2002-08-20 Microsolutions, Inc. Methods and implantable devices and systems for long term delivery of a pharmaceutical agent
NZ540351A (en) 1999-11-26 2006-05-26 Shionogi & Co NPY Y5 antagonists
DE60105547T3 (de) 2000-01-10 2014-12-31 Amylin Pharmaceuticals, Llc Verwendung von exendinen und deren agonisten zur behandlung von hypertriglyceridämie
AU2001237254A1 (en) 2000-03-08 2001-09-17 Novo-Nordisk A/S Lowering serum lipids
EP1272519A2 (en) 2000-03-16 2003-01-08 Bayer Aktiengesellschaft Regulation of human neuropeptide y-like g protein-coupled receptor
IL142707A0 (en) 2000-04-27 2002-03-10 Pfizer Prod Inc Methods of treating obesity using a neurotensin receptor ligand
US6444675B2 (en) 2000-05-10 2002-09-03 Bristol-Myers Squibb Company 4-alkyl and 4-cycloalkyl derivatives of dihydropyridine NPY antagonists
US6432960B2 (en) 2000-05-10 2002-08-13 Bristol-Myers Squibb Company Squarate derivatives of dihydropyridine NPY antagonists
WO2001087335A2 (en) 2000-05-17 2001-11-22 Eli Lilly And Company Method for selectively inhibiting ghrelin action
AU2001263230B2 (en) 2000-05-19 2005-03-10 Amylin Pharmaceuticals, Llc Treatment of acute coronary syndrome with glp-1
US6391881B2 (en) 2000-05-19 2002-05-21 Bristol-Myers Squibb Company Thiourea derivatives of dihydropyridine NPY antagonists
CZ20035A3 (cs) 2000-07-06 2003-05-14 Metabasis Therapeutics, Inc. Kombinace FBPázových inhibitorů a antidiabetických činidel užitečná při léčení diabetes
US6586403B1 (en) 2000-07-20 2003-07-01 Salpep Biotechnology, Inc. Treating allergic reactions and inflammatory responses with tri-and dipeptides
US6900226B2 (en) 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
US20020156010A1 (en) 2000-11-20 2002-10-24 Lustig Robert H. Method of treating obesity in adult patients exhibiting primary insulin hypersecretion
KR20080085082A (ko) * 2000-12-07 2008-09-22 일라이 릴리 앤드 캄파니 Ｇｌｐ-1 융합 단백질
RU2275207C2 (ru) 2000-12-14 2006-04-27 Амилин Фармасьютикалз, Инк. Способ снижения доступности питательного вещества, способ подавления аппетита
WO2002066479A1 (fr) 2001-02-23 2002-08-29 Banyu Pharmaceutical Co.,Ltd. Derives de l'isoindole
WO2002067918A1 (fr) 2001-02-27 2002-09-06 Banyu Pharmaceutical Co., Ltd. Nouveau derive de diallylmethylamine
IL159643A0 (en) 2001-07-26 2004-06-01 Schering Corp Substituted urea neuropeptide y y5 receptor antagonists
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
AU2002332054B2 (en) 2001-09-24 2007-11-08 Imperial Innovations Limited Modification of feeding behavior
WO2003057235A2 (en) 2002-01-10 2003-07-17 Imperial College Innovations Ltd Modification of feeding behavior
US8058233B2 (en) 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
CA2521784C (en) 2003-04-08 2012-03-27 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
CN1220702C (zh) 2003-07-30 2005-09-28 北京中科亚光生物科技有限公司 促胰岛素分泌肽及其用途
WO2005035761A1 (en) 2003-10-16 2005-04-21 Compugen Ltd. Splice variants of preproglucagon, glucagon-like peptide-1 and oxyntomodulin
MXPA06014031A (es) 2004-06-01 2007-10-08 Domantis Ltd Anticuerpos de fusion biespecificos con vida media de serica mejorada.
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
GB0504857D0 (en) 2005-03-09 2005-04-13 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
PT1891105E (pt) 2005-06-13 2012-06-27 Imp Innovations Ltd Análogos de oxintomodulina e seus efeitos sobre o comportamento da alimentação
CA2913805A1 (en) * 2005-11-07 2007-05-18 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
JP5297817B2 (ja) * 2006-02-22 2013-09-25 メルク・シャープ・アンド・ドーム・コーポレーション オキシントモジュリン誘導体
EP2474318A1 (en) 2006-06-07 2012-07-11 Human Genome Sciences, Inc. Albumin fusion proteins
GB0613196D0 (en) 2006-07-03 2006-08-09 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響

Also Published As

Publication number Publication date
SV2009003297A (es) 2010-02-17
RU2009126634A (ru) 2011-01-20
AU2007331257A1 (en) 2008-06-19
GT200900163A (es) 2011-11-22
TWI428346B (zh) 2014-03-01
US20130089545A1 (en) 2013-04-11
WO2008071972A1 (en) 2008-06-19
IL199247A (en) 2014-04-30
CA2672406A1 (en) 2008-06-19
US8101576B2 (en) 2012-01-24
NI200900116A (es) 2010-06-22
MY152840A (en) 2014-11-28
CO6210830A2 (es) 2010-10-20
JP2010513256A (ja) 2010-04-30
KR20090098843A (ko) 2009-09-17
MX2009006348A (es) 2009-06-30
EP1985304A2 (en) 2008-10-29
JP5669395B2 (ja) 2015-02-12
AU2007331257B2 (en) 2013-06-27
AR064334A1 (es) 2009-04-01
US20150018289A1 (en) 2015-01-15
TW200827370A (en) 2008-07-01
SG177226A1 (en) 2012-01-30
RU2492183C2 (ru) 2013-09-10
NZ578213A (en) 2012-04-27
EP1985304A3 (en) 2009-01-14
ECSP099513A (es) 2009-08-28
EP2422808A3 (en) 2012-06-13
US20090181885A1 (en) 2009-07-16
BRPI0721093A2 (pt) 2014-02-11
EP2422808A2 (en) 2012-02-29

Similar Documents

Publication Publication Date Title
CR10923A (es) Nuevos compuestos y sus efectos sobre el conductismo de la alimentacion
UA13518S (uk) Вивіска
UA15128S (uk) Вивіска
UA15144S (uk) Вивіска
UA15291S (uk) Вивіска
UA15381S (uk) Вивіска
UA15569S (uk) Вивіска
UA16793S (uk) Вивіска
UA16794S (uk) Вивіска
FI7185U1 (fi) Kaksinieluinen katiska
UA13182S (uk) Ярлик
UA13190S (uk) Етикетка
UA12015S (uk) Етикетка
UA12488S (uk) Етикетка
UA12491S (uk) Етикетка
UA12492S (uk) Етикетка
UA12513S (uk) Ярлик
UA12660S (uk) Ярлик
UA12661S (uk) Ярлик
UA12822S (uk) Етикетка
UA12835S (uk) Етикетка
UA12986S (uk) Етикетка
UA12989S (uk) Етикетка
UA13136S (uk) Етикетка
UA13178S (uk) Ярлик